$BCAX

$16.78 -$0.11 (0.65%) Pre-market

$BCAX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 66.2M shares outstanding

Who owns BCAX?

By type of holder

Institutions 100.0% Insiders 0.0% Everyone else 0.0%

Concentration Top 10 holders own 82.7%

Peter Kolchinsky 11.0% · Rajeev Shah 11.0%

Institutional ownership

100.0%

0 pts vs last qtr

Institutional holders

169

+24 vs last qtr

Net shares bought

+879.7K

by institutions in Q2 2026

New / sold out

38 / 14

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Jupiter Topco LLC NEW +3.2M
BlackRock, Inc. +1.0M

Biggest sellers in Q2 2026

Janus Henderson Group PLC SOLD OUT −3.3M
Citadel Advisors LLC −1.4M

Who is planning to sell?

Notices of proposed sale, last 12 months

$15.1M

48 notices from 7 people

Shares covered

671.4K

1.01% of the company

Arranged in advance

69%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Cohlhepp Ryan Officer 10b5-1 $3.48M
David Raben Officer $3.2M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2023–FY2025

+9325.3%

+870.84% a year

Each share's claim on the business

−98.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $24.3M

over 3 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years75% Under 1 year25%

Quarterly turnover

14.7%

of institutional shares changed hands

Top 10 managers, median time held

1.8 years

Super Investors

Investment managers reporting BCAX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
RC Ra Capital Management, L.P. 13D · 11.5%	7.3M	10.97%	Unchanged	2024	1.9%
Shares held by quarter Peak holding7.3M (Q1'26) Change over 8 quarters+300.0K Share of the company10.970% Disclosed stake13D · 11.5% Ra Capital Management, L.P.'s full portfolio →
TR T. Rowe Price Investment Management, Inc.	6.3M	9.58%	−267.3K (−4.0%)	Q3 '25	0.1%
Shares held by quarter Peak holding6.6M (Q1'26) Change over 8 quarters+6.3M Share of the company9.580% T. Rowe Price Investment Management, Inc.'s full portfolio →

Ra Capital Management, L.P.

13D · 11.5%

7.3M

% of company

10.97%

Change vs last qtr

Unchanged

Held since

2024

T. Rowe Price Investment Management, Inc.

6.3M

% of company

9.58%

Change vs last qtr

−267.3K (−4.0%)

Held since

Q3 '25

28 more super investors behind a free account

See every manager holding Bicara Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting BCAX on Form N-PORT; together they hold 25.8% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
TR T. Rowe Price Small-Cap Stock Fund, Inc. T. Rowe Price Small-Cap Stock Fund, Inc.	$64.7M	2.2M	3.29%	0.70%	June 30, 2026
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$49.8M	1.7M	2.53%	0.00%	June 30, 2026

T. Rowe Price Small-Cap Stock Fund, Inc.

Position value

$64.7M

% of company

3.29%

% of the fund

0.70%

As of

June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$49.8M

% of company

2.53%

% of the fund

0.00%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Bicara Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
PK Peter Kolchinsky 5%+ holder 13D · 11.5%	7.3M	11.00%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company11.000% Disclosed stake13D · 11.5% View the 13D/G filing →
RS Rajeev Shah 5%+ holder 13D · 11.5%	7.3M	11.00%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company11.000% Disclosed stake13D · 11.5% View the 13D/G filing →

Peter Kolchinsky

5%+ holder13D · 11.5%

7.3M

% of company

11.00%

Change vs last qtr

—

Held since

—

Rajeev Shah

5%+ holder13D · 11.5%

7.3M

% of company

11.00%

Change vs last qtr

—

Held since

—

5 more holders behind a free account

See every insider and 5%+ holder of Bicara Therapeutics Inc.

Comments